Tech Company Inital Public Offerings
Harmony Biosciences IPO
Harmony Biosciences, based in Plymouth Meeting, debuted as a public company on 8/18/2020.
Transaction Overview
Company Name
Announced On
8/18/2020
Transaction Type
IPO
Amount
$127,200,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $78.0 million to fund external clinical development for the potential new indications for pitolisant in PWS, MD and pediatric narcolepsy through clinical development; andthe remainder for working capital, business development opportunities, a potential milestone payment to Bioprojet and general corporate purposes, including to support the continued commercialization of WAKIX in the United States.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
630 W Germantown Pike 220
Plymouth Meeting, PA 19462
USA
Plymouth Meeting, PA 19462
USA
Phone
Undisclosed
Website
Email Address
Overview
Harmony Biosciences (Nasdaq: HRMY) is an innovative biopharmaceutical company dedicated to identifying, developing, and commercializing novel treatment options for patients with rare diseases. With an emphasis on Central Nervous System (CNS) disorders, our goal is to push the boundaries of what science can do to improve the lives of patients.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/18/2020: Grafana Labs venture capital transaction
Next: 8/19/2020: Xos Trucks venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs